Table 3. Clinical trials in patients with solid tumours with CAM.
| Year | Cancer type | CAM combined with | Number of patients | Outcome | Reference |
|---|---|---|---|---|---|
| 1997 | Lung stage IIIa, IIIb, IV (NSCLC & SCLC) | No other drugs (Prior chemo or radiation therapy or both) | 49 - CAM: 22 NSCLC & 3 SCLC - no CAM: 20 NSCLC & 4 SCLC |
NSCLC: increased median survival time SCLC: no significant difference in median survival time |
[71] |
| 2000 | Breast cancer (mastectomy) | No other drugs | 54 -28 CAM -26 no CAM |
Reduced change in temperature, heart & respiratory rate and monocyte count after surgery | [74] |
| 2001 | Lung stage IIIa, IIIb, IV (NSCLC) | No other drugs (Prior chemo or radiation therapy or both) | 47 - CAM: 33 patients - No CAM: 14 patients |
Not indicated | [72] |
| 2004 | Lung stage I, II, IIIa | -control: Flomoxef -CAM: flomoxef + CAM |
- Control: 16 patients - CAM: 10 patients |
Significant reduced duration of SIRS | [73] |
Abbreviations: NSCLC: non-small-cell lung cancer; SCLC = small-cell lung cancer; CAM = clarithromycin; SIRS = Systemic inflammatory response syndrome.